ライフサイエンスコーパス: interleukin-18

1 ugh expression, activation, and secretion of interleukin-18.

2 ived interferon (IFN)-a and monocyte-derived interleukin-18.

3 ity and with circulating levels of CXCL9 and interleukin-18.

4 uent release of mature interleukin-1beta and interleukin-18.

5 ponsive to stimulation by interleukin-12 and interleukin-18.

6 Interleukin 18, a pro-Th1 cytokine produced by enterocyt

7 We show that interleukin-18, a gene linked to diseases with sex-speci

8 We hypothesize that interleukin-18, a proinflammatory cytokine, induces endo

9 Apart from urine clusterin and interleukin-18, all other urinary biomarkers were elevat

10 on decreased expression of gamma interferon, interleukin-18, alpha interferon 16, and RNase L.

11 Here we show that interleukin 18, an anorexigenic cytokine, can act on neu

12 ingle cell RNA sequencing analysis, suggests interleukin 18 and CD95 signalling may trigger activatio

13 expression of the pro-inflammatory cytokine interleukin 18 and decreased expression of Serpin a3b, a

14 nd aspartate aminotransferase, and the DAMPs interleukin 18 and HMGB1 were reduced.

15 formities had significantly higher levels of interleukin 18 and IP-10 but lower levels of hepatocyte

16 Interleukin 18 and kidney injury molecule 1 discriminate

17 ition is more strongly associated with urine interleukin 18 and kidney injury molecule 1 in children

18 For interleukin 18 and kidney injury molecule 1, the areas u

19 For interleukin 18 and kidney injury molecule 1, the odds ra

20 ation of the cytokines interleukin-1beta and interleukin-18 and a lytic form of cell death termed pyr

21 the spleen and liver and reduced amounts of interleukin-18 and alpha/beta interferon secreted in the

22 leukin-10 and 1.7- and 3.0-fold increases in interleukin-18 and CCR 5, respectively.

23 Interleukin-18 and IL-1beta, which are cytokines of the

24 display diminished cell death and decreased interleukin-18 and interleukin-1B production, when infec

25 Myocardial protein expression of interleukin-18 and monocyte chemoattractant protein-1, k

26 inflammatory cytokines interleukin-1beta and interleukin-18 and pyroptosis, a form of phagocyte cell

27 inflammatory cytokines interleukin-1beta and interleukin-18 and pyroptotic cell death that causes the

28 the association between circulating level of interleukin-18 and systemic lupus erythematosus (SLE).

29 lation between the pro-inflammatory cytokine interleukin-18 and the anti-atherogenic adipokine adipon

30 ytes are a source of biologically functional interleukin-18 and thus are capable of playing an initia

31 nd ultrasensitive detection of the cytokines interleukin-18 and tumor necrosis factor-alpha.

32 nflammatory cytokines (interleukin 1beta and interleukin 18) and the antiinflammatory cytokine interl

33 peck-like protein containing a CARD), IL-18 (Interleukin-18) and IL-1beta (Interleukin- 1Beta) in obe

34 r (TNF) alpha, interleukin 1beta (IL-1beta), interleukin 18, and interleukin 6; chemokines CCL2, CCL4

35 (neutrophil gelatinase-associated lipocalin, interleukin 18, and kidney injury molecule-1).

36 in 6, interferon gamma-inducible protein 10, interleukin 18, and tumor necrosis factor alpha) and neg

37 MAIT cells was dependent on monocyte-derived interleukin 18, and was reduced in patients with HCV inf

38 ncluding interleukin-15, interleukin-17, and interleukin-18, and clinical trials of these agents are

39 ver-type fatty acid binding protein, urinary interleukin-18, and cystatin C) were measured in 1,635 u

40 ammasome, secretion of interleukin-1beta and interleukin-18, and pyroptosis.

41 ed lipocalin (NGAL), monomeric NGAL (mNGAL), interleukin-18, and standard biomarkers were measured at

42 had higher systemic levels of interleukin-6, interleukin-18, and tumor necrosis factor alpha than tho

43 nterleukin-6, interleukin-8, interleukin-10, interleukin-18, and tumor necrosis factor-alpha.

44 nterleukin-6, interleukin-8, interleukin-10, interleukin-18, and tumor necrosis factor-R2 were each s

45 the interleukin 10 receptor alpha chain and interleukin 18, are excellent candidates for Ibdq1.

46 Levels of interleukin-1beta and interleukin-18 at the end of integration of hemoadsorpti

47 [CRP], Chitinase 3-like protein-1 [CHI3L1], Interleukin 18 Binding Protein [IL-18BP], soluble Tumor

48 increased C-reactive protein, ferritin, and interleukin 18 binding protein, which in turn had direct

49 To accomplish this, interleukin-18 binding protein (IL-18BP) and tumor necro

50 Treatment with interleukin-18 binding protein decreased inflammation as

51 s have potential implications for the use of interleukin-18 binding protein for treatment of chronic

52 by blocking its biological activity with the interleukin-18 binding protein in the murine model of se

53 rleukin-6, were randomized to receive either interleukin-18 binding protein or vehicle approximately

54 se mice with a predicted low mortality rate, interleukin-18 binding protein significantly increased m

55 In mice with increased risk of dying, interleukin-18 binding protein slightly decreased mortal

56 IFN-gamma) receptor, IFN resistance protein, interleukin-18 binding protein, IFN-alpha/beta binding p

57 sis had decreased survival when treated with interleukin-18 binding protein.

58 topontin (DPT), beta-crystallin B1 (CRYBB1), interleukin-18-binding protein (IL18BP) and vascular end

59 th factors, transforming growth factor beta, interleukin-18-binding protein, semaphorin, and five ser

60 ompatibility complex class I molecule and an interleukin-18-binding protein.

61 ts through larger increases in RE, PGLO, and interleukin-18 but without impacting the RAAS.

62 kine induction (including interleukin-12 and interleukin-18), but was bereft of interferon-alpha indu

63 This bioactivity is neutralized by anti-interleukin-18, but not anti-interleukin-12 antibodies.

64 inflammatory cytokines interleukin-1beta and interleukin-18 by macrophages in response to alum in vit

65 of cg03636183 in F2RL3 were associated with interleukin-18 concentration (-0.11 pg/mL, 95% CI: -0.19

66 Recently, the interleukin-18 cytokine gene (IL18) was reported to be a

67 ule-1 increased over time, and the levels of interleukin-18 declined over time.

68 In the second stage, endogenous IL-1beta and interleukin 18 further amplify IL-36gamma synthesis.

69 A homologue of interleukin 18 has been identified from rainbow trout, O

70 Interleukin-18 has been demonstrated to be an important

71 Serum interleukin-18 has been reported to be elevated in patie

72 Human interleukin-18 (hIL-18) is a cytokine that plays an impo

73 5% amino acid sequence identities with human interleukin-18 (hIL-18)-binding protein (hIL-18BP), a na

74 recently shown that early administration of interleukin 18 (IL-18) after bone marrow transplantation

75 Circulating levels of the cytokine interleukin 18 (IL-18) are elevated in obesity.

76 hylococcus are capable of causing release of interleukin 18 (IL-18) from keratinocytes and that S. au

77 The cytokine interleukin 18 (IL-18) is also cleaved by caspase-1 and

78 t the deubiquitinase Cyld prevents excessive interleukin 18 (IL-18) production in the colonic mucosa

79 Interleukin 18 (IL-18) promotes atherosclerotic plaque f

80 ly resistant A/J mice released low levels of interleukin 18 (IL-18) upon infection with Salmonella ty

81 or necrosis factor alpha (TNF-alpha) but not interleukin 18 (IL-18), convalescent myocardial inflamma

82 ammation-associated genes, such as those for interleukin 18 (IL-18), IL-18BP, and caspase 1.

83 (6 x 10(6) CFU) resulted in the induction of interleukin 18 (IL-18), tumor necrosis factor alpha (TNF

84 alCer) and measured B cell activation during interleukin 18 (IL-18)-induced chronic inflammation.

85 me intracellular parasitic protozoa involves interleukin 18 (IL-18)-mediated interferon gamma (IFN-ga

86 ation with EPA led to a greater reduction in interleukin-18 (IL-18) (-7.0% +/- 2.8% compared with -0.

87 The unique cytokine interleukin-18 (IL-18) acts synergistically with IL-12 t

88 ls of gamma interferon and reduced levels of interleukin-18 (IL-18) and IL-10 in the serum of the Del

89 Because interleukin-18 (IL-18) and IL-12 stimulate IFN-gamma pro

90 ivating caspase-1, resulting in secretion of interleukin-18 (IL-18) and IL-1beta.

91 vestigated the in vitro effects of combining interleukin-18 (IL-18) and IL-2 on human lymphocytes.

92 speck-like protein containing a CARD (ASC), interleukin-18 (IL-18) and interleukin-1beta(IL-1beta) p

93 ed secretion of the proinflammatory cytokine interleukin-18 (IL-18) and multiantigen targeting could

94 y cytokines interleukin-1beta (IL-1beta) and interleukin-18 (IL-18) as well as pyroptotic cell death.

95 tinocytes results in increased production of interleukin-18 (IL-18) binding protein (IL-18BP).

96 r viral immune-modulatory genes, encoding an interleukin-18 (IL-18) binding protein, an IL-1beta rece

97 Interleukin-18 (IL-18) can regulate osteoblast and osteo

98 Interleukin-18 (IL-18) functions as a proinflammatory cy

99 ported to promote NSCLC development, whereas interleukin-18 (IL-18) has an undefined role.

100 Extreme elevation of serum interleukin-18 (IL-18) has been observed specifically in

101 Interleukin-18 (IL-18) has potent immunomodulatory effec

102 inflammatory protein 1 beta (MIP-1beta), and interleukin-18 (IL-18) in 131 patients with chronic HCV

103 NGAL), Kidney injury molecule-1 (KIM-1), and interleukin-18 (IL-18) in cirrhotic patients with AKI.

104 The in vivo role of endogenous interleukin-18 (IL-18) in modulating gamma interferon (I

105 Interleukin-18 (IL-18) is a costimulatory factor for int

106 Interleukin-18 (IL-18) is a critical proinflammatory cyt

107 Interleukin-18 (IL-18) is a newly described cytokine, fo

108 Interleukin-18 (IL-18) is a novel proinflammatory cytoki

109 Interleukin-18 (IL-18) is a pleiotropic cytokine central

110 Interleukin-18 (IL-18) is a pleiotropic cytokine implica

111 Interleukin-18 (IL-18) is a pleiotropic pro-inflammatory

112 Interleukin-18 (IL-18) is a pro-inflammatory cytokine, a

113 Interleukin-18 (IL-18) is a proinflammatory cytokine imp

114 Interleukin-18 (IL-18) is a unique cytokine that modulat

115 Interleukin-18 (IL-18) is an acute-phase proinflammatory

116 Interleukin-18 (IL-18) is an important regulator of inna

117 Human Interleukin-18 (IL-18) is an omnipresent proinflammatory

118 Interleukin-18 (IL-18) is reported as an important regul

119 Administration of Cas-1 products, interleukin-18 (IL-18) or IL-1beta, protected three of t

120 munotherapy, we found that components of the interleukin-18 (IL-18) pathway are upregulated on tumour

121 Interleukin-18 (IL-18) plasma level and latent class ana

122 Interleukin-18 (IL-18) produced by activated antigen-pre

123 stically, Tak1 activation leads to increased interleukin-18 (IL-18) production, whereas blockade of I

124 Interleukin-18 (IL-18) promotes inflammatory responses t

125 site Tbx21-CNS-3, and the expression of the interleukin-18 (IL-18) receptor; IL-18 induced T-bet exp

126 Administration of exogenous interleukin-18 (IL-18) regulates experimental acute graf

127 inflammasome as the major pathway leading to interleukin-18 (IL-18) release and restriction of S Typh

128 mory T cells with interleukin-12 (IL-12) and interleukin-18 (IL-18) results in tightly regulated prog

129 to limit T-cell exhaustion, and constitutive interleukin-18 (IL-18) secretion to enhance immune funct

130 Endothelial cell-derived interleukin-18 (IL-18) selectively expands a T-cell popu

131 tatic growth, which was mediated by impaired interleukin-18 (IL-18) signaling.

132 proinflammatory and proatherogenic cytokine interleukin-18 (IL-18) stimulates SMC proliferation, we

133 Intestinal interleukin-18 (IL-18) stimulation elicited tolerogenic

134 Here we show that interleukin-18 (IL-18) suppresses adiponectin transcript

135 ethyl ester (BAA473) can induce secretion of interleukin-18 (IL-18) through activation of the inflamm

136 The use of interleukin-18 (IL-18) together with IL-12 induced high

137 ranscription of the proinflammatory cytokine interleukin-18 (IL-18) was significantly higher in PVAN

138 Equivalent levels of active interleukin-18 (IL-18) were detected in the lungs of mic

139 n hosts encode homologous proteins that bind interleukin-18 (IL-18) with high affinity and inhibit IL

140 tions, decreased placental bed expression of interleukin-18 (IL-18) with increased production of temp

141 th pancytopenia had sustained high levels of interleukin-18 (IL-18) with low levels of IL-18 binding

142 Interleukin-18 (IL-18), a pro-inflammatory cytokine, is

143 enolase (NSE), a marker of brain damage, and interleukin-18 (IL-18), an innate immune marker, mainly

144 ere prevalent and included gamma interferon, interleukin-18 (IL-18), and the immunosuppressive, fibro

145 e the level of Toll-like receptor 4 (TLR-4), interleukin-18 (IL-18), and uric acid as markers of the

146 ), and urinary kidney injury markers such as interleukin-18 (IL-18), connective tissue growth factor

147 Interleukin-18 (IL-18), IL-1beta, IL-6, and tumor necros

148 It has recently been suggested that, interleukin-18 (IL-18), in addition to IL-12, contribute

149 phil gelatinase-associated lipocalin (NGAL), interleukin-18 (IL-18), kidney injury molecule-1 (KIM-1)

150 RD, caspase-1, interleukin-1beta (IL-1beta), interleukin-18 (IL-18), nucleotide-binding domain, leuci

151 mphocytes activation by differentiating into interleukin-18 (IL-18)- and IL-15-producing cells in an

152 ophages activated NK cells in a contact- and interleukin-18 (IL-18)-dependent manner, whereas monocyt

153 anism in the spleen, but both pyroptosis and interleukin-18 (IL-18)-driven natural killer (NK) cell r

154 ease of the interferon gamma inducing factor interleukin-18 (IL-18).

155 lso called interleukin-1gamma (IL-1gamma) or interleukin-18 (IL-18).

156 eron gamma, tumor necrosis factor alpha, and interleukin-18 (IL-18).

157 ection have identified a protective role for interleukin-18 (IL-18).

158 of the inflammasome and limits secretion of interleukin-18 (IL-18).

159 Existing evidence suggests that interleukin-18 (IL-18; an IL-1 family cytokine) is eleva

160 iated cytotoxicity (familial HLH) and excess interleukin-18 (IL-18; macrophage activation syndrome) p

161 actor (bFGF; P = .04) and increase in plasma interleukin-18 (IL-18; P < .01).

162 CL10/interferon-inducile protein 10 [IP-10], interleukin 18 [IL-18], CCL2/monocyte chemoattractant pr

163 amma inducible protein (IFI16), and cytokine interleukin 18 (IL18) in individuals with periodontitis,

164 g inducible nitric oxide synthase (iNOS) and interleukin 18 (IL18), suggesting Hg-induced inflammator

165 Interleukin-18 (IL18) is a cytokine playing a role in T-

166 Interleukin-18 (IL18) participates in atherogenesis thro

167 enterocolitis is due to up-regulation of the interleukin-18 (IL18) signaling pathway, and pharmacolog

168 unctional polymorphisms in the gene encoding interleukin-18 (IL18), a cytokine belonging to the IL-1

169 lational activation of interleukin-1beta and interleukin-18 in inflammation and apoptosis.

170 ine levels, and messenger RNA expressions of interleukin-18 in kidney, interleukin-6, indoleamine 2,3

171 trophil gelatinase-associated lipocalin, and interleukin-18 in predicting early graft function after

172 rthermore, we demonstrated the importance of interleukin-18 in preventing alveolar macrophage endotox

173 xpression in il-18r-/- mice and injection of interleukin-18 in rag2-/- and micro-/- mice.

174 We sought to determine the role of interleukin-18 in sepsis by blocking its biological acti

175 ed with type A F. tularensis did not release interleukin-18 in vitro, a response that requires the ac

176 previously uncharacterized states such as an interleukin-18-induced polyfunctional natural killer cel

177 Interleukin-18 (interferon-gamma-inducing factor) is ano

178 locyte-macrophage colony-stimulating factor, interleukin-18, interferon-gamma and possibly interleuki

179 eukin-23p40, interleukin-13, interleukin-17, interleukin-18, interferongamma, transforming growth fac

180 erging or enlarged roles for interleukin-10, interleukin-18, interleukin-9, chemokines, activation of

181 Interleukin-18 is a potent inducer of interferon-gamma b

182 Human keratinocyte-secreted interleukin-18 is biologically active, in that condition

183 Interferon-gamma-inducing factor (IGIF, interleukin-18) is a recently described cytokine that sh

184 The baseline plasma interleukin-18 level after 6 months of the AD was predic

185 , ATX, and Mac2BP levels declined by week 2, interleukin 18 levels declined by the end of treatment,

186 h altered glycosylation of IgG and increased interleukin-18 levels in the plasma.

187 cts suggest that cigarette smoking increases interleukin-18 levels through the decrease in DNA methyl

188 il gelatinase-associated lipocalin and serum interleukin-18 levels were not different between groups.

189 atients showed elevated NLRP3, caspase-1 and interleukin-18 messenger RNA expression and, using a mou

190 phage endotoxin tolerance through studies of interleukin-18 messenger RNA expression in il-18r-/- mic

191 r oncolytic HSV-1 vectors, expressing murine interleukin 18 (mIL-18), soluble murine B7-1 [B7-1-immun

192 oluble CD163 (sCD163), interleukin 6 (IL-6), interleukin 18, monocyte chemoattractant protein (MCP-1)

193 nterleukin-6, interleukin-8, interleukin-10, interleukin-18, monocyte chemotactic protein-1, high-mob

194 Interleukin-18 mRNA and intracellular protein levels are

195 selected non-bone marrow derived skin cells, interleukin-18 mRNA is constitutively expressed by human

196 Pro-interleukin-18 must be cleaved by interleukin-1-beta-con

197 in use, and additional agents that modulate interleukin-18, myeloid-related proteins 8 and 14, natur

198 ostoperative (0-6 hours after surgery) urine interleukin 18, neutrophil gelatinase-associated lipocal

199 stically, Notch4 suppressed the induction by interleukin-18 of amphiregulin, a cytokine necessary for

200 and the decreases in both CRP (P = .01) and interleukin 18 (P = .02) levels were smaller in underwei

201 The roles of the interleukin 1 (IL-1) and interleukin 18 pathways in host defense are well establi

202 and activation of the ATM/YAP1/precursor of interleukin 18 (pro-IL-18) pathway in the intestinal epi

203 Increased expression of pro-interleukin-18 (pro-IL-18) mRNA and activated IL-18 prot

204 By immunohistochemistry, interleukin-18 protein is detected in basal keratinocyte

205 sults in the secretion of immunoprecipitable interleukin-18 protein.

206 y NK cells in response to interleukin-12 and interleukin-18, providing a mechanistic link between CD3

207 the co-stimulation receptors ICOS, CD28 and interleukin 18 receptor.

208 g Tlr1, Tlr3, Tlr6, Tlr7, Tlr9, Tlr11 or the interleukin-18 receptor (IL-18R).

209 We identified interleukin-18 receptor accessory protein (IL18RAP) 3' u

210 ludes the type I interleukin-1 receptor, the interleukin-18 receptor, and a growing family of Toll-li

211 eins, including Nt-proBNP, thrombospondin-2, interleukin-18 receptor, gelsolin, and activated C5.

212 ooth muscle cells (VSMCs) express functional interleukin-18 receptors (IL-18Rs), composed of alpha an

213 (>0.3 x 10(9) /L) at screening and low serum interleukin-18 relative change at pre-treatment baseline

214 nts with high blood eosinophils or low serum interleukin-18 response are potential subgroups for furt

215 nts with high blood eosinophils or low serum interleukin-18 response are potential subgroups for furt

216 e knockout of a single Toll-like receptor or interleukin 18 resulted only in minor impairment of bact

217 -) mice were given injections of recombinant interleukin 18 (rIL18) or saline (control) during DSS ad

218 d inflammasome driving interleukin-1beta and interleukin-18 secretion.

219 on-beta production and gasdermin D-dependent interleukin-18 secretion.

220 on of vascular endothelial growth factor and interleukin-18 signaling in dermatomyositis keratinocyte

221 with Toll-like receptor, interleukin-1, and interleukin-18 signaling.

222 8alphaalpha(+) IEL development by modulating interleukin-18 signalling.

223 s of proinflammatory cytokines TNF-alpha and interleukin 18 than the HEV-infected pigs without detect

224 min-D-dependent pyroptosis and processing of interleukin-18, thereby destroying the replicative niche

225 d exposure to inflammatory mediators such as interleukin-18, these cells rapidly release type 2 cytok

226 by inflammatory markers ranged from 1.5% for interleukin 18 to 14.2% for C-reactive protein, and 16.1

227 T-cell product (huCART19-IL18) that secretes interleukin-18 to enhance antitumor activity.

228 nes, including the key Th1-inducing cytokine interleukin-18, upon Salmonella challenge than those fro

229 ain replicating HCV and respond by producing interleukin-18 via the inflammasome and by activating NK

230 ne associated, while the caspase-1 substrate interleukin-18 was cytosolic.

231 regulation of endothelin receptor type B and interleukin-18 was validated.

232 ome in monocytes, or after neutralization of interleukin-18, which is regulated by the inflammasome.